- BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
- BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
- BeiGene Reports First Quarter 2024 Financial Results and Business Updates
- BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
- Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
- BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
- BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
- Pi Health Raises Over $30M in Series A to Revolutionize Cancer Care and Clinical Trials
- First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
- BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
More ▼
Key statistics
On Wednesday, Beigene Ltd (BGNE:NSQ) closed at 151.28, 19.15% above the 52 week low of 126.97 set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 149.36 |
---|---|
High | 152.12 |
Low | 147.03 |
Bid | 149.20 |
Offer | 159.91 |
Previous close | 153.11 |
Average volume | 147.87k |
---|---|
Shares outstanding | 104.54m |
Free float | 102.83m |
P/E (TTM) | -- |
Market cap | 16.64bn USD |
EPS (TTM) | -7.57 USD |
Data delayed at least 15 minutes, as of May 29 2024 21:00 BST.
More ▼